The p53 tumor suppressor protein activates transcription and induces cell death. A close homologue of p53, termed p73, is expressed in transactivating (TA) forms that induce growth arrest and apoptosis much like p53. However, the p73 gene contains a second promoter, giving rise to the expression of p73DN, a species of p73 proteins that lack the N-terminal transactivation domain. We show here that the expression of p73DN is induced by p53 on the mRNA and protein level. The promoter that regulates p73DN expression in human cells was cloned and found to be activated by p53, as well as by p73TA, directly through a specific DNA element. The p73DN proteins, that are thereby expressed, bound to p53-responsive promoter DNA, competed with p53 for DNA binding, antagonized the activation of transcription by p53, and prevented p53-induced cell death. In addition, a transcriptional repressor domain was identified within the splicing variant p73DNa. The combination of p73DNa and mdm2 antagonized p53 more strongly than either p73Na or mdm2 alone. Blocking endogenous p73DN by a trans dominant fragment, or its removal by siRNA, increased the activity of a p53-responsive promoter in cells that contain a wild type p53 gene. Thus, the induction of p73DN expression by p53 establishes an autoregulatory feedback loop that keeps the trigger of cell death under tight control.
Introduction
The tumor suppressor gene p53 is the most frequently mutated gene in human malignancies. Its product interacts with the DNA of specific promoters and activates transcription. In parallel, activated p53 induces cell cycle arrest or apoptosis (Levine, 1997; Vousden, 2000) . However, p53 is bound and destabilized by the mdm2 protein, helping to avoid excessive cell death (Ashcroft and Vousden, 1999; Freedman et al., 1999; Momand et al., 2000) . A close homologue of p53, termed p73, is expressed in different isoforms from differentially spliced mRNA. The first p73 proteins to be identified contain identical aminoterminal and central domains and a variety of carboxyterminal portions, termed a, b, etc. (De Laurenzi et al., 1998; Kaghad et al., 1997) . The p73a isoform represents the largest p73 protein species. The b, g etc. isoforms are smaller and arise from exon-skipping at the 3' portion of the corresponding mRNA. These proteins induce p53-responsive promoters by their transactivating (TA) domain, and they trigger growth arrest and apoptosis much like p53 (Jost et al., 1997; Kaghad et al., 1997) .
Despite the similar set of their target genes, a number of biological differences were found between p53, p73, and a third family member, p63/p51 (Osada et al., 1998) . p53, but not p73 and p63, is bound by a number of viral oncoproteins (Dobbelstein and Roth, 1998; Higashino et al., 1998; Marin et al., 1998; Prabhu et al., 1998; Reichelt et al., 1999; Roth and Dobbelstein, 1999; Roth et al., 1998b; Steegenga et al., 1999; Wienzek et al., 2000) . Unlike p53, the p73 and p63 genes do not represent bona fide tumor suppressor genes, and tumors rarely contain p73 or p63 mutations (Hagiwara et al., 1999; Mai et al., 1998; Nishi et al., 1999; Nomoto et al., 1998; Takahashi et al., 1998) . p53 7/7 mice develop tumors with high frequency (Donehower et al., 1992) , whereas p73 7/7 and p63 7/7 mice do not show an increased tumor incidence (Mills et al., 1999; Yang et al., 1999 . These observations clearly indicate that p53 and its relatives have different biological functions. This may be caused by differences in the respective gene structures.
The p73 gene was found to contain a second transcriptional start site, giving rise to the expression of p73N, a species of p73 proteins that lack the Nterminal transactivation domain . p73DN proteins have various carboxyterminal ends, due to differential splicing at the 3' portion of the mRNA, yielding a, b, etc. isoforms in analogy to the p73TA proteins. Similar findings were reported for the p63 gene (Hibi et al., 2000; , whereas no DN forms of human or murine p53 have been described. The TA forms of p73 are transcriptionally induced by E2F and contribute to E2F-mediated apoptosis (Irwin et al., 2000; Stiewe and Putzer, 2000) . In contrast, until recently, little has been known about the regulation of p73DN expression. Since p73DN proteins, based on the comparison with the p53 domain structure, contain a DNA binding domain that recognizes p53-responsive promoters, but do not contain an aminoterminal transactivation domain, it was suggested that p73DN antagonizes the activity of p53 (Stiewe et al., 2002; . In this case, the p73 gene might be necessary to overcome the p53-induced growth arrest or apoptosis, at least when mdm2 and the related mdmx protein (Shvarts et al., 1996) are not expressed in sufficient amounts to do so. Accordingly, p73 7/7 mice show reduced proliferation of hippocampal neurons and enhanced apoptosis of developing sympathetic neurons (Pozniak et al., 2000) . This suggests that the p73 gene and its DN products may be required to prevent an excess of p53 activity.
A function of p73DN as a negative regulator of p53 could be performed most efficiently if p73DN expression was enhanced by p53. This is true in the case of the p53 antagonist mdm2. The expression of the mdm2 gene is induced by p53 through transcriptional activation of a second, downstream promoter (Barak et al., 1994; Juven et al., 1993; Zauberman et al., 1993) . This raises the question whether p53 also affects the levels of p73DN. A recent report shows that the p73DN promoter can be induced by p53 (Grob et al., 2001) . Our data confirm and extend these findings.
We show here that p53 directly activates a second promoter within the human p73 gene, giving rise to enhanced p73DN mRNA and protein levels. p73DN, in turn, blocks p53-mediated transcriptional activation and apoptosis, thus providing a regulatory feedback loop for the efficient control of p53 activity.
Results
p53 induces the transcription of the DN mRNA species from the human p73 gene
The first transcriptional start site of the p73 gene gives rise to transactivating (TA) p73 proteins, whereas transcription from the second start site, located behind the third exon of the gene, yields mRNA with a unique exon termed 3' that is joined to the downstream exons common to p73TA and p73N ( Figure 1a ). This structure of the p73 gene was previously determined in the murine system . We found a 3' exon to be present in the human p73 gene as well, first by homology search and subsequently by detection of the corresponding mRNA in human cells (Figure 1b) . To test whether p53 influences the transcription of either form of p73, p53 was expressed by adenovirus transduction or transient transfection in human cells that lack endogenous p53, namely H1299 and Saos2 cells. Both p73 mRNA species were detected by semiquantitative reverse transcription and polymerase chain reaction (RT -PCR). As shown in Figure 1b , the amount of p73DN mRNA was strongly increased upon p53 expression. In contrast, the p73TA mRNA species and the GAPDH control remained unchanged. Hence, p53 specifically enhances the amount of p73DN mRNA.
To address whether p73DN mRNA levels may be elevated by endogenous p53 upon DNA damage, LS174T cells, a human colon adenocarcinoma cell line (Rutzky et al., 1980) with wild type p53 (Arita et al., 1997) , were treated with the DNA damage inducing agent camptothecin. It was previously suggested that p73TA mRNA can be induced by camptothecin in this system (Chen et al., 2001) and that the first promoter of the p73 gene may be induced by p53, giving rise to expression of p73TA. In contrast to this, we found that, upon treatment with camptothecin, LS174T cells have strongly enhanced levels of p73DN but not p73TA mRNA (Figure 1b) . H1299 cells (p53 7/7) were transduced with an adenovirus expression vector for p53, Saos2 cells (p53 7/7) were transiently transfected to express p53, and LS174T cells were treated with 300 nM camptothecin from a dimethylsulfoxide (DMSO) based stock solution for 24 h, or mock-treated with DMSO as indicated. The mRNA levels of p73TA and p73DN were subsequently determined by semiquantitative RT -PCR, and compared to mRNA from empty vector or mock controls. The number of PCR cycles used is indicated below each pair of lanes. GAPDH expression was monitored in parallel as a loading control
The p73DNa protein levels are elevated in response to p53
The increase in p73DN mRNA levels prompted us to determine the corresponding protein levels in response to p53 activation. LS174T cells were treated with camptothecin. p53 activity was then assessed by immunoblot, quantifying the levels of p53 itself and of the p53 target gene product p21/cip1/waf1. The amounts of both proteins were elevated in response to camptothecin (Figure 2a) , indicating that the drug enhanced p53 levels and activity. In parallel, a p53-induced protein was detected by immunoblot analysis, using a polyclonal rabbit antibody to p73a (Figure 2a ). This antibody recognizes both p73TAa and p73DNa. To discriminate the two p73a proteins, p73TAa and p73DNa were each expressed by transient transfection and analysed on the same blot. It was found that the p73a proteins could be distinguished by size. Importantly, the size of the p53-induced p73a protein in LS174T cells corresponded to p73Na, not p73TAa. This strongly suggests that the levels of p73Na are specifically increased by p53.
To confirm the identity of the detected protein, HAtagged p73 and p63 proteins were generated by transcription and translation in vitro, followed by Western blot analysis. An anti-tag antibody detected the TA and DN forms of p73a and p73b, as well as p63TAg, whereas the polyclonal rabbit anti-p73 antibody, that was used in Figure 2a , detected the two p73a proteins exclusively (Figure 2b ). These data indicate that this antibody does not react with other p53 homologues than p73a. In addition, p73 proteins were immunoprecipitated from LS174T cells using a murine monoclonal antibody against all isoforms of p73 (Marin et al., 1998) , followed by Western blot detection using the rabbit polyclonal antibody against p73a. A band corresponding to p73DNa was detected only when the cells had been treated with camptothecin, and when the monoclonal anti-p73 antibody was used for immunoprecipitation, but not after mock treatment or when a control antibody was used for precipitation ( Figure 2c ). These findings further indicate that p73DNa protein levels are increased as a response to DNA damage in cells that contain a wild type p53 gene.
We then determined whether the transient overexpression of p53 in p53 7/7 cells can also elevate p73DNa protein levels. Saos2 cells were transfected with a p53 expression plasmid, and p73DNa was detected by immunoblot. Increased amounts of p73DNa were found in p53-expressing cells but not in vector-transfected cells (Figure 2d ), indicating that p53 can stimulate p73Na expression.
To clarify further whether the induction of p73DNa expression depends on p53, LS174T cells (wild type p53) were transduced with adenovirus vectors to express p53, or the trans-dominant negative p53 mutant p53R273H, in the presence or absence of camptothecin. It was found that adenovirus-expressed p53 alone was sufficient to increase the levels of p73DNa. p53 overexpression and simultaneous treatment with camptothecin further augmented p73Na, whereas p53R273H reduced the amounts of p73DNa in Figure  1b . Cellular proteins were separated by polyacrylamide gel electrophoresis, followed by immunoblot. In parallel, Saos2 cells were transiently transfected with expression plasmids for non-tagged p73TAa or p73DNa as indicated. These Saos2 cell lysates were mixed with lysate of non-treated LS174T cells at a ratio of 1 : 1400 and 1 : 5000, respectively, and processed as the samples from camptothecin-treated LS174T cells, for comparison of protein sizes. Upon treatment with camptothecin, p53 and p21 (also known as CIP1/WAF1) were detected by monoclonal antibodies, to monitor p53 activation by camptothecin. p73a was detected with a polyclonal rabbit antibody. A background band (*) was consistently observed using this antibody, serving as a loading control. (b) p73 and p63 proteins with HA tags at the carboxytermini were generated by transcription and translation in vitro, followed by immunoblot analysis. For detection, an antibody against the HA tag, or the same polyclonal rabbit antibody against p73 as in (a), was used as indicated. (c) LS174T cells were treated with camptothecin, or mock-treated as indicated and as in (a). The cells were lysed, and subjected toimmunoprecipitation, using a monoclonal antibody against p73, or a control antibody against SV40 T antigen. The precipitated material was separated by electrophoresis followed by immunoblot and detection using the polyclonal rabbit antibody against p73 as in (a). (d) Saos2 cells (p53 7/7) were transfected with an expression plasmid for p53, or an empty vector plasmid, as indicated and as in Figure  1b , followed by Western blot analysis using the polyclonal rabbit antibody against p73. (e) LS174T cells were transduced with adenovirus vectors to express b-galactosidase or p53 as indicated. Simultaneously, the cells were treated with camptothecin, or mocktreated with DMSO. After 24 h, p73DNa was detected as in (a) p53 induces p73DN expression NN Kartasheva et al . These promoter mutants were tested in Saos2 cells for activation by p53, as in (b). (d) Deletion constructs of the p73DN promoter, lacking the promoter sequence from the 5' end to each of the sites mutated in (c), were analysed in H1299 cells for activation by p53, as described in (b) . (e) In vitro interaction of the p53-responsive element within the p73DN promoter with p53. The DNA fragment RE4 (underlined in Figure 3a ) was radiolabeled and incubated with p53 protein, followed by electrophoretic mobility shift the presence of camptothecin (Figure 2e ). Thus, DNA damage increases the levels of p73Na protein through p53. Taken together, these results (Figures 1 and 2 ) indicate that p53 specifically activates the expression of p73DN on the mRNA and protein level.
The human p73 gene contains a downstream, p53-responsive promoter Next, we asked whether the human p73 gene contains a second promoter (termed p73DN promoter hereafter) that is directly inducible by p53. A DNA fragment corresponding to the region upstream of the p73DN coding sequence (7969 to 716, cf. Figure 3a) was PCR-amplified from human genomic DNA and cloned into a luciferase reporter plasmid. This construct was transiently transfected into human p53 7/7 cells, with or without a p53 expression plasmid. Luciferase activity was strongly enhanced by p53, and also by the TA forms of p63g, p73a, and p73b ( Figure 3b ), indicating that p53 and its transcriptionally active homologues can efficiently induce the p73DN promoter. To elucidate the mechanism of p53 response, putative p53 binding sites that correspond to the previously defined consensus RRRCWWGYYYN (0 -13) RRRC WWGYYY (R=A or G, W=A or T, Y=C or T, N=any nucleotide) (Funk et al., 1992; were identified in the p73DN promoter, and each site was mutated in the reporter construct, as outlined in Figure 3a . All promoter mutants were tested for p53 responsiveness in luciferase assays. A mutation within the sequence element -310 GGGCAAGCTG AGGCCTGCCCC GGACTTGGAT 7280 (nucleotides corresponding to the consensus in bold), but none of the other mutations, abolished promoter activation by p53 (Figure 3c ). Promoter deletion constructs were used to reveal that the region upstream of this element was dispensable to allow induction by p53, whereas further truncation at the 5' end abolished p53 responsiveness (Figure 3d ). Hence, this element is required for p53-mediated activation of the p73DN promoter. These findings are in agreement with a recent report (Grob et al., 2001) .
The sequence element found to be crucial for p53-mediated promoter activation was analysed for p53 binding by electrophoretic mobility shift assay (EMSA). We found that p53 bound this element (Figure 3e, lanes 1 -3) . The interaction was competed with non-labeled p73DN promoter DNA and with the DNA from a heterologous p53-responsive element, derived from the p21/cip1/waf1 gene, but not when mutations were introduced into the sequences of the competitors (Figure 3e, lanes 4 -8) . p73TAa, p73TAb, p73DNa, p73DNb, and p63TAg, as well as p53, bound the p73N promoter element, and supershift experiments using specific antibodies confirmed the identity of the protein -DNA complexes (Figure 3f ). In conclusion, the p73DN promoter element allows specific binding of p53 and its homologues to the DNA. These results strongly suggest that the p73DN promoter is directly activated by p53 and its TA-homologues through a specific DNA element.
p73DN antagonizes p53-mediated transcriptional activation
What consequences can be expected from the enhanced p73N expression in response to p53? p73DN proteins contain a DNA binding domain but apparently lack an aminoterminal transactivation domain. This domain structure suggests that p73DN may act as an antagonist to p53. To test this directly, we co-transfected H1299 cells (p53 7/7) with expression plasmids for p53 and its TA homologues, and two splicing variants of p73DN, p73DNa and p73DNb, along with a luciferase reporter plasmid containing the p53-responsive mdm2 promoter (Roth et al., 1998a) , followed by reporter assays to quantify promoter activity. It was found that both forms of p73DN inhibited p53-induced transcription (Figure 4a ). Inhibition by p73DNb was moderate, and p73DNb displayed some intrinsic capacity to transactivate. In contrast, p73DNa acted as a potent inhibitor of p53 and its TA homologues. To determine the effect of p73N proteins on endogenous p53-responsive genes, p53 and p73DN proteins were coexpressed in H1299 cells using adenovirus vectors. The p53-responsive gene products p21, mdm2 and bax were induced by p53, but their levels were strongly reduced when p73N proteins were expressed together with p53 ( Figure 4b ). These findings indicate that p73N proteins counteract the transcriptional activation by p53.
To address the mechanism(s) by which p73DNa and p73DNb inhibit p53-mediated transactivation, it was tested whether they can bind to the same type of DNA elements as p53. Electrophoretic mobility shift assays revealed that, indeed, p73DNa and p73DNb bound to the p53-responsive element of the p21/cip1/waf1 promoter at least as efficiently as p53 itself ( Figure  4c , lanes 1 -6). When mixtures of p73 proteins and p53 were incubated with the same DNA element, p73 proteins successfully competed with p53 for DNA binding (Figure 4c , lanes 7 -12; cf. (Stiewe et al., assay (EMSA). The monoclonal antibody 421 against p53 was added as indicated. This antibody activates specific DNA-binding by p53 (Hupp et al., 1992) . Non-labeled competitors, derived from the fragment RE4 of the p73DN promoter, or from the p21/cip1/ waf1 promoter, with or without a mutation in the p53 binding site, were added in 10-fold or 100-fold excess as specified above the lanes. The positions of the protein-DNA complexes are indicated by arrows. (f) The p53-responsive element within the p73DN promoter was analysed as in (e), using p53 as well as HA-tagged p73 and p63 proteins that were generated by transcription and translation in vitro (cf. Figure 2b) . The monoclonal antibody 421 against p53 and the monoclonal antibody HA.11 against the HA tag were added as indicated. Note that the DN species of p73 have a lower electrophoretic mobility on a native gel than the TA isoforms, despite the higher molecular weights of the latter, perhaps due to differences in the isoelectric point p53 induces p73DN expression NN Kartasheva et al Figure 4 p73DN antagonizes p53-mediated transactivation. (a) p73DN inhibits the transcriptional activity of p53 and TA species of p53 homologues. Expression plasmids for p53 (100 ng), p73TAa (100 ng), p73TAb (25 ng), p63TAg (100 ng) and/or the indicated p73DN species (100 ng) were transfected in H1299 cells, and p53 activity was determined by co-transfecting a luciferase reporter plasmid (50 ng) that contained the p53-responsive element of the mdm2 promoter (Roth et al., 1998a) , and subsequent luciferase assay. The luciferase activity obtained with p53 alone was set 100%, and the other values were normalized accordingly. The mean 2002)). This raises the possibility that p73DNa and p73DNb may prevent the interaction of p53 with the DNA of p53-responsive promoters in cells, thereby antagonizing p53-mediated transactivation. Nevertheless, this would still not explain why p73DNa was more efficient to inhibit p53-induced transcription than p73DNb. To elucidate this, the carboxyterminal domain of p73DNa, i.e. the only part of the protein that is different from p73DNb, was fused to the GAL4 DNA binding domain (DBD) and expressed in the presence of a reporter plasmid that contained GAL4 binding DNA sequences upstream of the thymidine kinase (tk) promoter. We found that the carboxyterminal domain of p73a proteins was capable of repressing transcription to a similar extent as the known repressor protein E1B-55 kDa from adenovirus (Yew et al., 1994) (Figure 4d ). No repression was observed when the corresponding carboxyterminal domain of p73b was fused to the GAL4 DBD (data not shown). These findings strongly argue that p73Na actively represses transcription through its carboxyterminal domain. The fact that p73a proteins but not the p73b proteins contain a repressor domain also provides an explanation for the finding that the transcriptionally active p73TAa protein induces a p53-responsive reporter to a lesser extent than p73TAb ( Roth et al., 1998b) , Figures 3b and 4a) .
In addition to p73DN, the mdm2 protein functions as a negative regulator of p53. Therefore, we analysed the inhibition of p53-mediated transcription by the simultaneous expression of p73DNa and mdm2. Expression plasmids for p53, p73DNa and mdm2 were transfected into H1299 cells in different combinations, along with a p53-responsive luciferase reporter plasmid. We found that p73DNa and mdm2 together reduced the transcriptional activity of p53 to a far greater extent than either of the two proteins alone (Figure 4e ). This suggests that the two p53-induced gene products, p73DNa and mdm2, can provide a tighter control of p53 activity than just one of these p53-antagonists.
p73DN antagonizes p53-mediated apoptosis
Since p73DN proteins inhibit p53-mediated transcription, it was of interest to test if they also inhibit p53-induced apoptosis. To address this directly, p53, p73DNa and p73DNb were expressed in different combinations by transient transfection of Saos2 cells. Cells expressing p53 were then identified by immunofluorescence, and apoptosis was assessed by morphology and DNA staining intensity. p53-mediated induction of apoptosis was significantly inhibited by both p73DN proteins in this assay (Figure 5a ). To confirm these results, H1299 cells were transduced to express p53, p73DNa and p73DNb, alone or in combinations, using recombinant adenoviruses. Cell death was detected by crystal violet staining of the cells that remained on the dish. Again, p73DNa and p73DNb each inhibited p53-mediated cell death ( Figure  5b ), reflecting the regulation of p53-induced transcription. On the other hand, some growth inhibitory effect was also conferred by the p73DN proteins alone in this assay ( Figure 5b ) and in colony forming assays (data not shown). This is reminiscent of the mdm2 protein, that also inhibits p53-induced apoptosis (Haupt et al., 1996) but blocks cell proliferation when overexpressed (Brown et al., 1998) . To further confirm the inhibition of p53-mediated apoptosis by p73DN proteins, H1299 cells were transduced with adenovirus expression vectors as above, and harvested after 24 h. Subsequently, poly(ADP-ribose) polymerase (PARP) was detected by immunoblot. The PARP protein (113 kDa) is specifically cleaved into two characteristic fragments (89 kDa and 29 kDa) early during apoptosis but not during necrosis. Immunodetection of the fulllength protein and the larger cleavage fragment represents, therefore, a means to determine the induction of apoptosis (Lazebnik et al., 1994) . Accordingly, cells that were transduced with a p53 expression vector mainly contained the PARP cleavage fragment (Figure 5c, lane 4) . In contrast, after transduction with expression vectors for p73DN values and standard errors obtained from at least three experiments are shown. (b) p73DN proteins antagonize p53-mediated activation of endogenous p53-responsive genes. H1299 cells were transduced by adenovirus vectors to express p53 (multiplicity of infection (MOI)=10) and p73DN proteins (MOI=50) in the indicated combinations, keeping the total MOI at 60 with an adenovirus expression vector for b-galactosidase. Twenty-four hours after transduction, the p53-responsive gene products p21 and mdm2 were detected by Western blot analysis. Subsequently, lamin B was detected on the same blot as a loading control. The bax protein was detected on a parallel blot using the same samples. (c) p73DN proteins compete with p53 for DNA binding. A radiolabeled p53-binding portion of the p21 promoter was incubated as indicated with p53 and p73 proteins (each synthesized by translation in vitro, cf. Figure 2b ), or combinations of these proteins, followed by EMSA. Note that the DN species of p73 have a lower electrophoretic mobility on a native gel than the TA isoforms, despite the higher molecular weights of the latter, perhaps due to differences in the isoelectric point. (d) p73DNa contains a transcriptional repressor domain. The carboxyterminal portion (244 amino acids) of p73a was fused to a GAL4 DNA-binding domain (DBD). Expression plasmids for the GAL4 DBD alone (1.1 mg), or a protein generated by fusion of the GAL4 DBD with the carboxyterminal portion of p73a (0.11 mg or 1.1 mg), or a fusion protein of the GAL4 DBD with the known repressor E1B-55 kDa (Yew et al., 1994) (0.11 mg or 1.1 mg), were transfected into Saos2 cells together with two reporter plasmids (0.2 mg each). The reporter constructs, as outlined above the diagram, contained a pentamer of GAL4-responsive DNA elements upstream of the thymidine kinase (tk) promoter and the firefly luciferase reporter gene, or the tk promoter alone upstream of the renilla luciferase gene (Yew et al., 1994) . The activities of both luciferase species were determined in triplicate (arbitrary units), and in each case, the ratio of these activities is shown with the standard error. (e) p73DNa inhibits p53 activity in cooperation with mdm2. H1299 cells were transfected with expression plasmids for p53 (100 ng), p73DNa (10 ng) and mdm2 (1 mg), or the corresponding vector plasmids, as well as a reporter plasmid (100 ng) containing the p53-responsive element of the mdm2 promoter. Luciferase assays were carried out to determine p53 activity. Normalized luciferase activities from three experiments and the standard errors are shown p53 induces p73DN expression NN Kartasheva et al proteins, or upon co-expression of p53 and p73DN proteins, only full-length PARP was detected ( Figure   5c ). This indicates that p73DN proteins block p53-mediated apoptosis.
Endogenous p73DN negatively regulates p53 activity
Finally, we asked whether regulation of p53 by p73DN can be observed under physiological conditions, i.e. whether endogenous intracellular levels of p73DN are sufficient to antagonize p53. In one approach to address this, we used a fragment of p73a (amino acids 327 -636), termed p73DD, that was previously used to block the activity of p73TA proteins in a transdominant fashion (Irwin et al., 2000; Zaika et al., 2001) . This fragment consists of the carboxyterminal portion of p73a, comprising the oligomerization domain. Therefore, p73DD competitively blocks the oligomerization of p73 proteins. First, we tested whether p73DD interferes with the activity of p73DNa to antagonize p53. H1299 cells (p53 7/7) were transfected with expression plasmids for p53, p73DNa and p73DD, as well as a p53-responsive reporter construct. Quantification of reporter expression revealed that p73DD completely abolished the inhibitory effect of p73DNa on p53 activity ( Figure 6a ). Next, we used the same expression construct for p73DD to antagonize endogenous p73 in LS174T cells (p53 wild type). The expression of the p73 antagonist led to an approximately threefold increase in activity of a p53-responsive promoter (Figure 6b ). When camptothecin was used to activate p53, the addition of p73DD further increased its activity.
To corroborate these findings, cells derived from the SK-N-SH line (human neuroblastoma, p53 wild type) were transfected with small interfering RNA (siRNA) oligonucleotides (Elbashir et al., 2001) , targeted against p73 mRNA. The reduced p73 protein levels (Figure 6c ) resulted in enhanced levels of the p53-responsive gene product p21/CIP1/WAF1 (Figure 6c ).
Neither the fragment p73DD nor the siRNA used in these experiments can distinguish between p73DN and p73TA proteins. However, the inactivation of p73TA would presumably result in downregulation of p53-responsive genes, or at least not upregulate them. Therefore, the results are compatible with the hypothesis that it was the inhibition of endogenous p73DN by p73DD (Figure 6b ), or the reduction of its expression by siRNA (Figure 6c) , that resulted in the activation of a p53-responsive promoter.
These results strongly suggest that endogenous p73DN proteins act to limit the activity of p53-responsive promoters under physiological conditions, both in the absence and in the presence of genotoxic stress. Therefore, we propose that p73DN proteins establish a regulatory feedback loop that controls the activity of p53 (Figure 6d ).
Discussion
The results shown here reveal that p53 induces the expression of its own antagonist, p73DN. This is the Figure 5 p73DN antagonizes p53-induced apoptosis. Saos2 cells were transiently transfected with plasmids to express p53 (12.5 ng), either alone, or with p73DNa (25 ng), or with p73DNb (25 ng). After 96 h, the cells that expressed p53 were detected by immunofluorescence and evaluated for the hallmarks of apoptosis (blebbing, reduction of the DNA content as revealed by staining with DAPI) by a person unaware of the identity of the samples. Less than 5% of the non-transfected cells were apoptotic. The proportion of apoptotic cells among the cells that expressed detectable p53 is shown as the mean of three independent experiments, with the standard error. This proportion was compared between the cells that expressed p53 alone, and those that expressed p53 together with one of the p73DN isoforms. The values were found to be different, the level of significance being P50.01 (**) or P50.05 (*) as indicated. (b) H1299 cells were transduced by adenovirus vectors to express p53 (MOI=50) and p73DN proteins (MOI=100) in the indicated combinations. The total MOI was kept at 150 using an expression vector for b-galactosidase. Twenty-four hours after transduction, detached cells were washed off the dish, and the remaining cells were stained with crystal violet. (c) H1299 cells were transduced as in (b), followed by immunoblot to detect poly(ADP-ribose) polymerase (PARP). The sizes of full-length PARP, and of the cleavage product that is typically found in apoptotic cells, are marked by arrows p53 induces p73DN expression NN Kartasheva et al second negative regulatory feedback loop found to control p53. The first feedback loop of this kind is established by the p53-mediated induction of the mdm2 gene, leading to the inhibition and destabilization of p53 by the mdm2 protein (Haupt et al., 1997; Kubbutat et al., 1997; Wu et al., 1993) . p73DN and mdm2 are each upregulated in response to p53, and in both cases, this is achieved through a second, downstream promoter that contains a p53 binding site. The two p53-induced factors are then each capable of reducing p53 activity. We propose that the two negative feedback loops together provide a more efficient and reliable system to control p53. The induction of p73DN by p53 was recently reported (Grob et al., 2001) . Here, we independently confirm this and provide additional clues to understand the negative feedback mechanism. In particular, we show that p73DNa actively represses transcription, and that it can increase the inhibition of p53 by mdm2 (Figure 4) . Most importantly, we show that, in two independent assay systems, the inactivation or the removal of endogenous p73 proteins leads to the activation of endogenous p53. This strongly suggests that a regulatory feedback loop between p53 and p73DN determines p53 activity under physiological conditions.
Another recent report (Nakagawa et al., 2002) comes up with a different conclusion. There, the authors argue that p73DN was induced by p73TA proteins but not by p53. The reasons for this discrepancy between their report and the results presented here together with those reported by Grob et al. (2001) may rely in the use of different cell species. The cells used in Nakagawa et al. (2002) were mostly derived from neuroblastomas. It is known that in these tumor cells, p53 is frequently mislocalized from the nucleus to the cytoplasm, resulting in the inactivation of p53 (Moll et al., 1995) . Thus, it is conceivable that p53 is less active than p73TA proteins in these cells. Further, despite the weaker activity of p53 observed by Nakagawa et al. (2002) , p53 still activated the p73DN promoter in their hands. Thus, we propose that each transcriptionally active member of the p53 family can activate the p73DN promoter, and that in many neuroblastoma cell species, p53 might be generally less active than p73TA proteins.
Nonetheless, because not only p53, but also the TA forms of p73 and p63 can act as inducers of p73DN expression (Figure 3) , and since the activity of p73TA and p63TA proteins can be blocked by p73DN ( Figure  4) , it is possible that p73DN proteins exert control not only over p53 itself, but also over the TA-homologues of p53. Thus, it seems that three species of activators, p53, p73TA and p63TA, can each induce at least two negative regulators, i.e. p73DN and mdm2, possibly establishing several overlapping regulatory feedback loops. The relative importance of these is likely to depend on the specific cell type, as does the expression of p53 homologues .
Initially, it was hypothesized that p73 may function as a tumor suppressor, in analogy to p53 (Jost et al., 1997; Kaghad et al., 1997) . However, it was found subsequently that p73 is not a bona fide tumor suppressor gene. Indeed, mutations of p73 are extremely rare in tumors (Mai et al., 1998; Nomoto et al., 1998; Takahashi et al., 1998) . The fact that p73 gene products serve as inducible p53 antagonists provides a stringent explanation for these observations. The involvement of p73DN in the negative regulation of p53, as outlined in Figure 6c , argues that nonmutated p73 may even be required for tumor growth, Figure 6 Endogenous p73DN inhibits the activity of p53. (a) A trans-dominant inhibitor of p73DN. H1299 cells were transfected with expression plasmids for p53 (100 ng), p73DNa (100 ng) and the p73-fragment p73DD (residues 327 -636 of p73TAa; 400 ng) in the indicated combinations, along with a reporter plasmid (50 ng) containing the p53-responsive element of the mdm2 promoter. Normalized luciferase activities from three experiments and the standard errors are shown. (b) LS174T cells (wild type p53) were transfected with the p53-responsive reporter plasmid (100 ng) as in (a), as well as an expression plasmid for the dominant-negative p73 fragment p73DD (1 mg), or empty vector plasmid. After 24 h, the cells were treated with camptothecin, or mock-treated as in Figure 1b . Luciferase activities were determined 24 h thereafter. (c) A derivative of SK-N-SH cells (wild type p53) were transfected with siRNA oligonucleotides targeting p73 mRNA, or control oligonucleotides. After 48 h, the cells were harvested, subjected to SDS-polyacrylamide gel electrophoresis, and transferred onto nitrocellulose. Total protein was visualized by Ponceau S staining as a loading control, and the membrane was probed with antibodies against p73 and p21/CIP1/WAF1. (d) Control of p53 activity by negative feedback. p53 induces p73N and several effectors of apoptosis. p73DN inhibits the activity of p53, thus providing a mechanism to limit p53-induced cell death p53 induces p73DN expression NN Kartasheva et al since it allows to overcome p53-mediated growth arrest.
Tight control of p53 is required to prevent excessive cell death. On the other hand, overexpression of a p53 antagonist can give rise to cancer, as in the case of mdm2 (Oliner et al., 1992) . Notably, p73 is overexpressed in a number or tumors ( (Irwin and Kaelin, 2001; Levrero et al., 2000) and references therein), and high p73DN levels were found in neuroblastomas (Kovalev et al., 1998) and breast carcinomas (Zaika et al., 1999) . Tumors of the same species frequently do not contain p53 mutations (Moll et al., 1992 (Moll et al., , 1995 . In these cases, p73DN isoforms may act as oncoproteins by inhibiting p53 and allowing cell proliferation.
As p63, like p73, contains a second promoter to express DN isoforms, this promoter might be regulated in analogy to the second p73DN promoter. Interestingly, however, p63N proteins and the corresponding mRNA are downregulated upon treatment of keratinocytes by ultraviolet irradiation (Liefer et al., 2000) . Since ultraviolet irradiation induces p53 activity (Perry et al., 1993) , this suggests that p53 may reduce, rather than increase, p63DN expression. Nevertheless, more direct assays are required to elucidate this issue. Transcriptionally active p53 homologues are conserved between Drosophila melanogaster and mammals (Brodsky et al., 2000; Jin et al., 2000; Ollmann et al., 2000) , whereas no p53-antagonist similar to mdm2 has been found in Drosophila. This raises the possibility that the expression of p53 homologues in 'DN'-forms may be a phylogenetically older way of controlling p53 activity, whereas mdm2 evolved more recently. p53 has long been known as the central 'guardian of the genome' (Lane, 1992) , coordinating a response of the cell to genotoxic stress (Oren, 1999; Vogelstein et al., 2000) and protecting the organism against malignant cell growth. However, its role as a 'death star' (Vousden, 2000) implies that p53 also causes danger to the cell, unless it is precisely regulated. To avoid a fatal overreaction, the cell employs p73DN to control p53.
Materials and methods

Cell culture and transfections
H1299 and Saos2 cells (both p53 7/7) were maintained in Dulbecco's modified eagle medium (DMEM; Life Technologies) with 10% fetal bovine serum (FBS). LS174T cells were cultivated in RPMI 1640 (Life Technologies) with 10% FBS. Transfections were done using Lipofectamine 2000 (Life Technologies) for H1299 cells, FuGene6 (Roche) for Saos2 and LS174T cells.
GTC AGT GGA TCT CGG CCT CCG TGA ACT CCT CCT TG, and cloned into pcDNA3, together with the lamin 5' untranslated region, using BamHI and XbaI.
All plasmids were confirmed by sequencing. An expression plasmid for the GAL4 DBD fused to adenovirus type 5 E1B-55 kDa and reporter plasmids containing the tk promoter with or without a GAL4 responsive element upstream were a gift from A Berk (Yew et al., 1994) . A pCMVneoBam expression plasmid containing the human cDNA encoding mdm2 (Oliner et al., 1992) was obtained from B Vogelstein.
Semiquantitative RT -PCR
H1299 cells were transduced with adenovirus vectors to express p53 or GFP alone, Saos2 cells were transfected to express p53, or with empty vector plasmid, and LS174T cells were treated with camptothecin or mock-treated. After 24 and 48 h, respectively, total RNA was prepared (Trizol Reagent, Life Technologies), followed by reverse transcription with Superscript II polymerase (Life Technologies) and PCR amplicification with Pfu turbo DNA polymerase (Stratagene). The primer used for reverse transcription of both p73 mRNA species was CAG GTG GCT GAC TTG GCC GTG CTG, and the PCR primers were as follows. p73DN forward: CGC CTA CCA TGC TGT ACG TCG GTG, p73TA forward: TGG AAC CAG ACA GCA CCT ACT TCG, p73 reverse (both TA and DN): TGC TGG AAA GTG ACC TCA AAG TGG. When amplifying GAPDH mRNA, the primer GGT TCA CAC CCA TGA CGA ACA TG was used for reverse transcription, and the primers TGA AGG TCG GAG TCA ACG GAT TTG GT and GCA GAG ATG ATG ACC CTT TTG GCT C for amplification.
Electrophoretic mobility shift assay (EMSA) p53 and its homologues were generated by in vitro transcription and translation using T7 RNA polymerase and rabbit reticulocyte lysate (Promega). To generate double stranded DNA, two oligonucleotides were annealed to each other, followed by a fill-in reaction in the presence or absence of radioactively labeled dNTPs. DNA binding was analysed by EMSA as described . The oligonucleotides employed had the following sequences. p73DN forward: GAT CGC GGC CGC GGG CAA GCT GAG GCC TGC CCC GGA CT, p73DN reverse: GGG ATC CAA GTC CGG GGC AGG CCT CAG CTT GCC CGC GGC CGC, p73DN mutant forward: GAT CGC GGC CGC GGG AAA TCT GAG GCC TGC CCC GGA AT, p73DN mutant reverse: GGG ATC AAA TTC CGG GGC AGG CCT CAG ATT TCC CGC GGC CGC, p21 forward: GAT CGC GGC CGC GAA CAT GTC CCA ACA, p21 reverse: GGG CAA CAT GTT GGG ACA TGT TCG CGG CCG C, p21 mutant forward: GAT CGC GGC CGC GAA AAT TTC CCA AAA, p21 mutant reverse: GGG CAA AAT TTT GGG AAA TTT TCG CGG CCG C.
Immunoblot
Proteins were separated on SDS polyacrylamide gels and transferred to nitrocellulose, followed by incubation with antibodies in PBS containing 5% milk powder and 0.05% Tween 20. Peroxidase-coupled secondary antibodies (whole immunoglobulin G to detect murine primary antibodies, Fab fragments to visualize the rabbit antibody to p73a; Jackson) were then detected by chemiluminescence (Pierce). Antibody Pab1801 to p53, antibody Ab-1 to p21/cip1/waf1 and antibody Ab-2 against poly(ADP-ribose) polymerase (PARP) were from Calbiochem. The monoclonal mouse antibody 2A10 against mdm2 was a gift from A Levine. The polyclonal rabbit antibody against p73a (amino acids 450-636) used in Figure 2 was from Silenus (cat # 90001500), that used in Figure 6 was from BD Pharmingen. Other monoclonal mouse antibodies were against bax (BD Transduction Laboratories), HA.11 against the HA tag (Babco), and against lamin B (Zymed).
Immunoprecipitation
LS174T cells (6610 6 ) were harvested in IP buffer (1000 ml; 50 mM Tris HCl pH 7.5; 150 mM NaCl; 2 mM EDTA; 0.2% Triton X-100; 0.3% Nonidet P-40) containing protease inhibitors (Complete Mini, Roche) and disrupted by 5 passages through a 28 G needle. After centrifugation, the supernatant (500 ml each) was pre-cleared with protein A sepharose beads (30 ml) for 30 min, and incubated with antibody (1 mg) and protein A sepharose beads (15 ml packed volume) for 12 h with gentle agitation. The beads were washed six times in IP buffer, and the attached proteins were further analysed by SDS gel electrophoresis and immunoblot. The antibody 419 against SV40 T antigen, and the antibody Ab-2 (E1-15) against p73 were from Calbiochem.
Immunofluorescence
Cells were fixed and incubated with antibodies as described (Roth et al., 1998a) . The p53 protein was stained with a polyclonal rabbit antibody (FL-393, Santa Cruz) that had been raised against full-length p53. p73 was stained with a mixture of two mouse monoclonal antibodies (Ab-1 and Ab-3 against p73, Calbiochem). Primary mouse antibodies were visualized by a secondary antibody coupled to Alexa 488 (Molecular probes). Primary rabbit antibodies were detected by an Alexa 594-labeled secondary antibody (Molecular probes). Prior to mounting (Fluoprep, bioMe´rieux), the cell nuclei were briefly stained using 4,6-diamidino-2-phenylindole (DAPI).
siRNA SK-N-SH cells (Biedler et al., 1973) are derived from a human neuroblastoma and contain wild type p53. A subclone derived from these cells (SH-IP, kindly provided by H Christiansen and B Berwanger) was used in this work. This cell line was employed because it responded to the treatment with siRNA with particularly high efficiency (our unpublished observations). Double stranded RNA molecules were prepared (Dharmacon) to target a control sequence (lamin B1: AAC GCG CTT GGT AGA GGT GGA) or p73 mRNA (AAC CAC GAG CTC GGG AGG GAC, corresponding to nt 696-716 of NM_005427.1) and transfected using Oligofectamine (Life Technologies) exactly as described (Elbashir et al., 2001) .
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